ArticleEuropean journal of medical research2026
Evaluation of serum HMGB1 levels in assessing the severity of pediatric sepsis and analysis of the therapeutic efficacy of blood purification modalities.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHigh Mobility Group Box 1 protein (HMGB1) plays a critical role in the pathogenesis of sepsis. However, its value in assessing disease severity and its relationship with blood purification therapy in pediatric sepsis remains underexplored.
objectiveThis study aims to investigate the value of serum HMGB1 in evaluating the severity of pediatric sepsis and its association with blood purification treatment.
methodsA retrospective observational cohort study was conducted. This study included 90 pediatric patients with sepsis and 21 healthy controls admitted from March 2022 to December 2023. Patients were stratified into a mild-severity group (n = 44) and a severe-severity group (n = 46) based on clinical criteria. Among the severe patients, 21 received continuous renal replacement therapy (CRRT). Of these, 6 were treated with a single-mode (CHDF) and 15 with a mixed-mode (CHDF + PE) blood purification strategy. Serum HMGB1 levels were measured using enzyme-linked immunosorbent assay (ELISA).
resultsSerum HMGB1 levels were significantly higher in the sepsis group compared to the healthy control group (P < 0.001). Within the sepsis cohort, HMGB1 levels were significantly elevated in the severe group versus the mild group (P < 0.001). Receiver operating characteristic (ROC) curve analysis indicated that HMGB1 had an area under the curve (AUC) of 0.921 for diagnosing severe sepsis, demonstrating superior performance compared to other inflammatory markers. CRRT treatment was associated with a significant reduction in HMGB1 and other inflammatory markers (P < 0.001). The survival rate in the mixed-mode treatment group was significantly higher than that in the single-mode group (86.7% vs. 16.7%, P = 0.006).
conclusionSerum HMGB1 levels are significantly associated with the severity of pediatric sepsis and show promising diagnostic value. Blood purification treatment is associated with a reduction in HMGB1 levels; however, the underlying mechanisms require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.